Drugs

, Volume 65, Issue 14, pp 1973–1989

Budesonide Inhalation Suspension for the Treatment of Asthma in Infants and Children

Review Article

Abstract

On the basis of the well recognised role of inflammation in the pathogenesis of asthma, anti-inflammatory therapy, in the form of inhaled corticosteroids, has become the mainstay of treatment in patients with persistent asthma. Budesonide inhalation suspension (BIS) is a nonhalogenated corticosteroid with a high ratio of local anti-inflammatory activity to systemic activity. Furthermore, BIS is approved in >70 countries for the maintenance treatment of bronchial asthma in both paediatric and adult patients (approval is limited to paediatric patients in the US and France).

Randomised, double-blind, placebo-controlled trials conducted in >1000 children have demonstrated the efficacy of BIS in children with persistent asthma of varying degrees of severity. In children frequently hospitalised with uncontrolled asthma, initiation of BIS therapy can reduce the need for emergency intervention. Moreover, limited data suggest that BIS is effective for the treatment of acute exacerbations of asthma in children and may reduce the need for short courses of oral corticosteroids.

BIS is well tolerated in children, with an adverse event profile similar to that of placebo, and no clinically relevant changes in adrenal function have been demonstrated during the course of short- and long-term (1-year) studies. Small but statistically significant reductions in growth velocity have been demonstrated with BIS over 1 year of treatment. However, available evidence suggests that growth effects are transient in children receiving budesonide and that these children eventually achieve full adult height.

References

  1. 1.
    Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. NIH Publication No. 02-3659. Issued January, 1995 (updated 2002). Management segment (chapter 7): updated 2003 from the 2002 document: 1-180 [online]. Available from URL: http://www.ginasthma.com [Accessed 2005 Aug 9]
  2. 2.
    AAAAI. Pediatric asthma: promoting best practice. Guide for managing asthma in children. Milwaukee (WI): American Academy of Allergy, Asthma & Immunology, 2004: 1–143Google Scholar
  3. 3.
    American Lung Association, Epidemiology & Statistics Unit, Research and Scientific Affairs. Trends in asthma morbidity and mortality. 2004 Apr [online]. Available from URL: http://www.texaslung.org/educationalresources/diseases/asthma/2004asthmatrends.pdf [Accessed 2005 Jul 22]
  4. 4.
    National Asthma Education and Prevention Program. Expert panel report: guidelines for the diagnosis and management of asthma: update on selected topics 2002. J Allergy Clin Immunol 2002; 110 (5 Suppl.): S141–219CrossRefGoogle Scholar
  5. 5.
    Jeffery PK. Remodeling and inflammation of bronchi in asthma and chronic obstructive pulmonary disease. Proc Am Thorac Soc 2004; 1: 176–83PubMedCrossRefGoogle Scholar
  6. 6.
    Tasche MJA, Uijen JHJM, Bernsen RMD, et al. Inhaled disodium cromoglycate (DSCG) as maintenance therapy in children with asthma: a systemic review. Thorax 2000; 55: 913–20PubMedCrossRefGoogle Scholar
  7. 7.
    Barnes PJ. Efficacy of inhaled corticosteroids in asthma. J Allergy Clin Immunol 1998 Oct; 102(4): 531–8PubMedCrossRefGoogle Scholar
  8. 8.
    Brogden RN, McTavish D. Budesonide: an updated review of its pharmacological properties and therapeutic efficacy in asthma and rhinitis. Drugs 1992 Sep; 44(3): 375–407PubMedCrossRefGoogle Scholar
  9. 9.
    Hvizdos KM, Jarvis B. Budesonide inhalation suspension: a review of its use in infants, children and adults with inflammatory respiratory disorders. Drugs 2000 Nov; 60(5): 1141–78PubMedCrossRefGoogle Scholar
  10. 10.
    Szefler SJ. Pharmacodynamics and pharmacokinetics of budesonide: a new nebulized corticosteroid. J Allergy Clin Immunol 1999 Oct; 104(4): S175–83CrossRefGoogle Scholar
  11. 11.
    Agertoft L, Andersen A, Weibull E, et al. Systemic availability and pharmacokinetics of nebulised budesonide in preschool children. Arch Dis Child 1999 Mar; 80(3): 241–7PubMedCrossRefGoogle Scholar
  12. 12.
    Pulmicort Respules [summary of product characteristics]. Luton: AstraZeneca UK Ltd, 2001 Jun 11Google Scholar
  13. 13.
    Pulmicort Respules (budesonide inhalation suspension) prescribing information. Wilmington (DE): AstraZeneca LP, 2004 MarGoogle Scholar
  14. 14.
    de Blic J, Delacourt C, Le Bourgeois M, et al. Efficacy of nebulized budesonide in treatment of severe infantile asthma: a double-blind study. J Allergy Clin Immunol 1996 Jul; 98(1): 14–20PubMedCrossRefGoogle Scholar
  15. 15.
    Ilangovan P, Pedersen S, Godfrey S, et al. Treatment of severe steroid dependent preschool asthma with nebulised budesonide suspension. Arch Dis Child 1993 Mar; 68(3): 356–9PubMedCrossRefGoogle Scholar
  16. 16.
    Wennergren G, Nordvall SL, Hedlin G, et al. Nebulized budesonide for the treatment of moderate to severe asthma in infants and toddlers. Acta Paediatr 1996; 85: 183–9PubMedCrossRefGoogle Scholar
  17. 17.
    Baker JW, Mellon M, Wald J, et al. A multiple-dosing, placebo-controlled study of budesonide inhalation suspension given once or twice daily for treatment of persistent asthma in young children and infants. Pediatrics 1999 Feb; 103(2): 414–21PubMedCrossRefGoogle Scholar
  18. 18.
    Kemp JP, Skoner DP, Szefler SJ, et al. Once-daily budesonide inhalation suspension for the treatment of persistent asthma in infants and young children. Ann Allergy Asthma Immunol 1999 Sep; 83: 231–9PubMedCrossRefGoogle Scholar
  19. 19.
    Shapiro G, Mendelson L, Kraemer MJ, et al. Efficacy and safety of budesonide inhalation suspension (Pulmicort Respules) in young children with inhaled steroid-dependent, persistent asthma. J Allergy Clin Immunol 1998 Nov; 102(5): 789–96PubMedCrossRefGoogle Scholar
  20. 20.
    Mellon M, on behalf of the Budesonide Inhalation Suspension Study Group. Efficacy of budesonide inhalation suspension in infants and young children with persistent asthma. J Allergy Clin Immunol 1999 Oct; 104: S191–9Google Scholar
  21. 21.
    Leflein JG, Gawchik SM, Galant SP, et al. Safety of budesonide inhalation suspension (Pulmicort Respules) after up to 52 weeks of treatment in infants and young children with persistent asthma. Allergy Asthma Proc 2001 Nov–Dec; 22(6): 359–66PubMedGoogle Scholar
  22. 22.
    Scott MB, Ellis MH, Cruz-Rivera M, et al. Once-daily budesonide inhalation suspension in infants and children <4 and ≥4 years of age with persistent asthma. Ann Allergy Asthma Immunol 2001 Dec; 87(6): 488–95PubMedCrossRefGoogle Scholar
  23. 23.
    Mendelson L, Cook D, Cruz-Rivera M, et al. Twice-daily budesonide inhalation suspension in infants and children <4 and ≥4 years of age with persistent asthma. J Asthma 2002 May; 39(3): 227–37PubMedCrossRefGoogle Scholar
  24. 24.
    Leflein JG, Szefler SJ, Murphy KR, et al. Nebulized budesonide inhalation suspension compared with cromolyn sodium nebulizer solution for asthma in young children: results of a randomized outcomes trial. Pediatrics 2002 May; 109(5): 866–72PubMedCrossRefGoogle Scholar
  25. 25.
    Chipps BE, Schnepp CM, Briscoe M. Budesonide inhalation suspension reduces the need for emergency intervention in pediatric asthma: a named-patient case series. J Asthma 2003 Dec; 40(8): 895–900PubMedCrossRefGoogle Scholar
  26. 26.
    Murphy KR, Fitzpatrick S, Cruz-Rivera M, et al. Effects of budesonide inhalation suspension compared with cromolyn sodium nebulizer solution on health status and caregiver quality of life in childhood asthma. Pediatrics 2003 Sep; 112(3): e212–9PubMedCrossRefGoogle Scholar
  27. 27.
    Delacourt C, Dutau G, Lefrançois G, et al. Comparison of the efficacy and safety of nebulized beclometasone dipropionate and budesonide in severe persistent childhood asthma. Respir Med 2003 Feb; 97 Suppl. B: S27–33PubMedCrossRefGoogle Scholar
  28. 28.
    Terzano C, Allegra L, Barkai L, et al. Beclomethasone dipropionate versus budesonide inhalation suspension in children with mild to moderate persistent asthma. Eur Rev Med Pharmacol Sci 2000; 4: 17–24Google Scholar
  29. 29.
    van Staa TP, Cooper C, Leufkens HG, et al. Children and the risk of fractures caused by oral corticosteroids. J Bone Miner Res 2003 May; 18(5): 913–8PubMedCrossRefGoogle Scholar
  30. 30.
    Kaye LD, Kalenak JW, Price RL, et al. Ocular implications of long-term prednisone therapy in children. J Pediatr Ophthalmol Strabismus 1993 May–Jun; 30(3): 142–4PubMedGoogle Scholar
  31. 31.
    Abernathy-Carver KJ, Fan LL, Boguniewicz M, et al. Legionella and Pneumocystis pneumonias in asthmatic children on high doses of systemic steroids. Pediatr Pulmonol 1994 Sep; 18(3): 135–8PubMedCrossRefGoogle Scholar
  32. 32.
    Brown ES, Chandler PA. Mood and cognitive changes during systemic corticosteroid therapy. Prim Care Companion J Clin Psychiatry 2001 Feb; 3(1): 17–21PubMedCrossRefGoogle Scholar
  33. 33.
    Sung L, Osmond MH, Klassen TP. Randomized, controlled trial of inhaled budesonide as an adjunct to oral prednisone in acute asthma. Acad Emerg Med 1998 Mar; 5(3): 209–13PubMedCrossRefGoogle Scholar
  34. 34.
    Matthews EE, Curtis PD, McLain BI, et al. Nebulized budesonide versus oral steroid in severe exacerbations of childhood asthma. Acta Paediatr 1999 Aug; 88(8): 841–3PubMedCrossRefGoogle Scholar
  35. 35.
    Daugbjerg P, Brenoe E, Forchhammer H, et al. A comparison between nebulized terbutaline, nebulized corticosteroid and systemic corticosteroid for acute wheezing in children up to 18 months of age. Acta Paediatr 1993 Jun–Jul; 82(6–7): 547–51PubMedCrossRefGoogle Scholar
  36. 36.
    Devidayal D, Singhi S, Kumar L, et al. Efficacy of nebulized budesonide compared to oral prednisolone in acute bronchial asthma. Acta Paediatr 1999 Aug; 88(8): 835–40PubMedCrossRefGoogle Scholar
  37. 37.
    Volovitz B, Bentur L, Finkelstein Y, et al. Effectiveness and safety of inhaled corticosteroids in controlling acute asthma attacks in children who were treated in the emergency department: a controlled comparative study with oral prednisolone. J Allergy Clin Immunol 1998 Oct; 102: 605–9PubMedCrossRefGoogle Scholar
  38. 38.
    Sano F, Cortez GK, Solé D, et al. Inhaled budesonide for the treatment of acute wheezing and dyspnea in children up to 24 months old receiving intravenous hydrocortisone. J Allergy Clin Immunol 2000 Apr; 105(4): 699–703PubMedCrossRefGoogle Scholar
  39. 39.
    Volovitz B, Soferman R, Blau H, et al. Rapid induction of clinical response with a short-term high-dose starting schedule of budesonide nebulizing suspension in young children with recurrent wheezing episodes. J Allergy Clin Immunl 1998 Apr; 101 (4 Pt 1): 464–9CrossRefGoogle Scholar
  40. 40.
    Scott MB, Skoner DP. Short-term and long-term safety of budesonide inhalation suspension in infants and young children with persistent asthma. J Allergy Clin Immunol 1999 Oct; 104 (4 Pt 2): S200-9Google Scholar
  41. 41.
    Szefler SJ, Lyzell E, Fitzpatrick S, et al. Safety profile of budesonide inhalation suspension in the pediatric population: worldwide experience. Ann Allergy Asthma Immunol 2004 Jul; 93(1): 83–90PubMedCrossRefGoogle Scholar
  42. 42.
    Berger WE, Qaqundah PY, Blake K, et al. Safety of budesonide inhalation suspension in infants aged six to twelve months with mild to moderate persistent asthma or recurrent wheeze. J Pediatr 2005 Jan; 146(1): 91–5PubMedCrossRefGoogle Scholar
  43. 43.
    Irani A-M, Cruz-Rivera M, Fitzpatrick S, et al. Effects of budesonide inhalation suspension on hypothalamic-pituitary-adrenal-axis function in infants and young children with persistent asthma. Ann Allergy Asthma Immunol 2002 Mar; 88(3): 306–12PubMedCrossRefGoogle Scholar
  44. 44.
    Skoner DP, Szefler SJ, Welch M, et al. Longitudinal growth in infants and young children treated with budesonide inhalation suspension for persistent asthma. J Allergy Clin Immunol 2000 Feb; 105(2): 259–68PubMedCrossRefGoogle Scholar
  45. 45.
    Daley-Yates PT, Richards DH. Relationship between systemic corticosteroid exposure and growth velocity: development and validation of a pharmacokinetic/pharmacodynamic model. Clin Ther 2004 Nov; 26(11): 1905–19PubMedCrossRefGoogle Scholar
  46. 46.
    Doull IJM. The effect of asthma and its treatment on growth. Arch Dis Child 2004 Jan; 89(1): 60–3PubMedCrossRefGoogle Scholar
  47. 47.
    Creese KH, Doull IJ. Effects of inhaled corticosteroids on growth in asthmatic children. Curr Allergy Asthma Rep 2001 Mar; 1(2): 122–6PubMedCrossRefGoogle Scholar
  48. 48.
    Childhood Asthma Management Program Research Group. Long-term effects of budesonide or nedocromil in children with asthma. N Engl J Med 2000 Oct; 343(15): 1054–63CrossRefGoogle Scholar
  49. 49.
    Agertoft L, Pedersen S. Effect of long-term treatment with inhaled budesonide on adult height in children with asthma. N Engl J Med 2000 Oct; 343(15): 1064–9PubMedCrossRefGoogle Scholar
  50. 50.
    de Jongste JC, Duiverman EJ. Nebulized budesonide in severe childhood asthma [letter]. Lancet 1989; 333(8651): 1388CrossRefGoogle Scholar
  51. 51.
    Grimfeld A, Lesbros D, Ostinelli J, et al. Long-term study of nebulised budesonide in young children with moderate to severe asthma [abstract no. 0204]. Eur Respir J 1994; 7 Suppl. 18: 27SGoogle Scholar
  52. 52.
    Lødrup Carlsen CKC, Carlsen KH, Nikander K, et al. Nebulized budesonide after hospitalisation for recurrent bronchial obstruction in children younger than 18 months. Pediatr Allergy Immunol 2000; 12: 159–65CrossRefGoogle Scholar
  53. 53.
    Nikander K, Turpeinen M, Wollmer P. The conventional ultrasonic nebulizer proved inefficient in nebulizing a suspension. J Aerosol Med 1999; 12(2): 47–53PubMedCrossRefGoogle Scholar
  54. 54.
    Smaldone GC, Cruz-Rivera M, Nikander K. In vitro determination of inhaled mass and particle distribution for budesonide nebulizing suspension. J Aerosol Med 1998; 11(2): 113–25CrossRefGoogle Scholar
  55. 55.
    Vikre-Jørgensen J, Agertoft L, Pedersen S. Dose titration of nebulized budesonide in young children. Pediatr Pulmonol 1997; 23: 270–7PubMedCrossRefGoogle Scholar
  56. 56.
    Everard ML, Clark AR, Milner AD. Drug delivery from jet nebulisers. Arch Dis Child 1992; 67: 586–91PubMedCrossRefGoogle Scholar
  57. 57.
    Geller DE, Kesser KC, Janssens HM, et al. Delivery of budesonide inhalation suspension (BIS) through an infant upper airway model [poster]. 99th International Conference of the American Thoracic Society; 2003 May 16–23; Seattle (WA)Google Scholar
  58. 58.
    Mellon M, Leflein J, Walton-Bowen K, et al. Comparable efficacy of administration with face mask or mouthpiece of nebulized budesonide inhalation suspension for infants and young children with persistent asthma. Am J Respir Crit Care Med 2000 Aug; 162(2): 593–8PubMedGoogle Scholar
  59. 59.
    Georgitis JW, McWilliams B, Cruz-Rivera M, et al. Effective once-daily administration of budesonide inhalation suspension by nebulizer with facemasks or mouthpieces for persistent asthma in infants and young children. Pediatr Asthma Allergy Immunol 2001; 15(1): 3–13CrossRefGoogle Scholar
  60. 60.
    McKenzie JE, Cruz-Rivera M. Compatibility of budesonide inhalation suspension with four nebulizing solutions. Ann Pharmacother 2004 Jun; 38(6): 967–72PubMedCrossRefGoogle Scholar
  61. 61.
    Dunlop KA, Carson DJ, Shields MD. Hypoglycemia due to adrenal suppression secondary to high-dose nebulized corticosteroid. Pediatr Pulmonol 2002 Jul; 34(1): 85–6PubMedCrossRefGoogle Scholar
  62. 62.
    Zwaan CM, Odink RJH, Delemarre-van de Waal HA, et al. Acute adrenal insufficiency after discontinuation of inhaled corticosteroid therapy [letter]. Lancet 1992 Nov; 340(8830): 1289–90PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2005

Authors and Affiliations

  1. 1.Allergy and Asthma Associates of Southern CaliforniaMission ViejoUSA

Personalised recommendations